Reistone Biopharma Appoints Dr. Qais Mekki as Senior Vice President, Head of International Development, US Site Head


Reistone Biopharma Company Limited (Reistone Biopharma) recently announced the appointment of Dr. Qais Mekki as Senior Vice President, Head of International Development, US Site Head. He will be based in Chicago and report to Min Irwin, CEO. 

Dr. Mekki will be responsible for setting up and managing a team focused on Clinical Development and Operations in US, EU, Canada, etc., and work closely with China headquarters.

Dr. Mekki has gained solid experience in the Pharmaceutical Industry for more than 30 years with senior management positions in MNC as well has wide experience in working with Asia teams. During his career he conducted numerous first-in-human, POC, and pivotal studies and filed multiple global and regional NDAs covering Cancer Pain, Kidney Transplantation, Rheumatoid Arthritis, Diabetes, and other diseases; moreover he had the opportunity to build and manage global teams.    

Prior to joining Reistone Biopharma, he served at Takeda for about 16 years, where he took leadership positions as Vice President in: Clinical Science, Pharmacovigilance, Translational Medicine, Clinical Pharmacology and Portfolio Management. Prior to that, he was a founding member of Fujisawa Pharmaceuticals in the United States, helping the company establish and improve its various functions, and had held executive positions for 14 years, responsible for Clinical Research, Clinical Pharmacology, and Medical Affairs.

Dr. Mekki received his Medical Degree from the University of Baghdad and PhD. in Clinical Pharmacology from the University of London.

At Reistone Biopharma US, Dr. Mekki is building a team of experienced professionals who will play a strategic leadership role in company's International Development. The clinical operations team is headed by Mr. Clement Popovici, an experienced leader in the industry, who joined Reistone Biopharma in January 2020, and rapidly built a team that is currently running multiple phase I-II programs.

Dr. Min Irwin, Chief Executive Officer of Reistone Biopharma, noted, “We are very excited to have Dr. Mekki to join the team, I believe he will play an essential role in building the U.S. team and deploying international clinical trial strategy. With that seasoned experience, including managing multiple programs in multiple therapeutic areas, from early development to post marketing, Dr. Mekki will bring Reistone Biopharma a wealth of global drug development experience. “

About Reistone Biopharma
Reistone Biopharma Company Limitedis a clinical stage bio-pharmaceutical company with a pipeline of immunology therapies focused on developing novel medicines aimed at treating autoimmune and inflammatory diseases that have high unmet needs. 
The company was founded in January 2018 and is headquartered in Shanghai. It currently employs about 100 people in China and the United States. Reistone Biopharma is currently running 7 phase II and 1 phase I studies globally, covering 4 assets. 
For more information about Reistone Biopharma, pleasevisit:

Date of issue:2020-07-17 00:00
Share to:
Read more articles